Skip to content

Harmony Biosciences

US · HRMY #2681 by market cap Listed 2020
32.59 -0.39 -1.18%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 33.00 +0.06%
After-hours 32.59 0.00%
42.8630.0932.592026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on HRMY?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -8.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 11.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall A+
ValuationGrowthProfitMomentumHealthAnalyst
Valuation A

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 10.8x Better than 76%
Forward P/E 8.0x Better than 90%
Price / Sales 2.0x Better than 57%
P/E vs own 5-yr range 17th pctl Better than 86%
Growth B+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 25.6% Better than 87%
Net income CAGR (3Y) -4.4% Better than 34%
Free cash flow CAGR (3Y) 34.1% Better than 77%
Profitability A

How much profit the business keeps from each dollar of sales and capital.

Gross margin 77.2% Better than 88%
Operating margin 24.0% Better than 83%
Net margin 18.3% Better than 77%
Return on equity 20.8% Better than 79%
Return on invested capital 16.4% Better than 84%
Momentum B-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -14.6% Better than 41%
6-month return 8.1% Better than 69%
12-month return (ex latest month) 5.3% Better than 41%
Distance below 52-week high 25.1% Better than 51%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.6x Better than 78%
Debt to assets 12.9% Better than 65%
Interest coverage 15.7x Better than 79%
Free cash flow / net income 219.2% Better than 80%
Analyst View B-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 62.5% Better than 39%
Upside to average target 45.8% Better than 63%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -3.47%
1M -15.79%
3M -14.39%
6M +3.86%
YTD -12.91%
1Y -2.40%
3Y +17.36%
5Y -15.92%

Key statistics

Price & volume

Prev close
32.98
Open
32.68
Day range
32.51 - 33.43
Avg price
32.83
Volume
582.64K
Turnover
19.13M
Amplitude
2.77%
52-week range
25.90 - 43.49

Valuation

P/E
12.03
P/E (TTM)
10.79
P/B
1.78
EPS
2.71
Net profit
159.14M
Net assets
1.07B

Share structure

Market cap
1.91B
Float cap
1.71B
Shares out
58.72M
Float shares
52.58M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-08-19
52-week range 38% of range
25.90 43.49

25.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-6.40M net over the window

Short interest

Shares short
6.66M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Harmony Biosciences (HRMY)?

Harmony Biosciences last traded at 32.59. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Harmony Biosciences's market cap?

About 1.91B.

What is the P/E ratio of Harmony Biosciences?

The trailing twelve-month P/E is 10.79, below its own 5-year average of 20.44 — toward the bottom of its historical range (16.59% percentile). See the Valuation tab for the full history.

Does Harmony Biosciences pay a dividend?

Harmony Biosciences does not currently pay a regular dividend.

Is Harmony Biosciences a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 47.50, which implies 45.8% upside from the current price. This is not investment advice.

What is Harmony Biosciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Harmony Biosciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.

Harmony Biosciences discussion 0 comments

Add a comment